"Official medicines" is the best online drugstore.

World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system.

The meds you need, reliable and hassle free! Top products of top brands.

The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe!

(eh-droe-FOE-nee-uhm KLOR-ide)
Enlon, Reversol, Tensilon
Class: Cholinergic muscle stimulant/anticholinesterase

 Action Facilitates myoneural junction impulse transmission by inhibiting acetylcholine destruction by cholinesterase.

 Indications Differential diagnosis of myasthenia gravis; adjunct in evaluating treatment of myasthenia gravis; evaluation of emergency treatment of myasthenic crises; reversal of neuromuscular blockade by curare gallamine or tubocurarine; treatment of respiratory depression due to curare overdose.

 Contraindications Hypersensitivity to anticholinesterases; mechanical intestinal and urinary obstruction.

 Route/Dosage

Diagnosis of Myasthenia Gravis

ADULTS: IM/IV 10 mg. CHILDREN > 34 KG: IV 2 mg. If no response after 45 sec, may titrate up to 10 mg in increments of 1 mg q 30–45 sec. or IM 5 mg as single dose. CHILDREN < 34 KG: IV 1 mg. If no response after 45 sec, may titrate up to 5 mg in increments of 1 mg q 30–45 sec or IM 2 mg as single dose. INFANTS: IV 0.5 mg.

Evaluation of Myasthenia Gravis Treatment

ADULTS: IV 1 to 2 mg 1 hr after ingestion of treatment drug.

Crisis Test

ADULTS: IV When respiration is adequate, give 1 mg initially. If after 1 min patient is not further impaired, give additional 1 mg.

Curare Antagonist

ADULTS: IV 10 mg over 30–45 sec. Repeat prn up to maximum total dose of 40 mg.

 Interactions

Corticosteroids: May antagonize anticholinesterases in myasthenia gravis, producing profound muscular depression. Succinylcholine: Neuromuscular blockade produced by succinylcholine may be either prolonged or antagonized.

 Lab Test Interferences None well documented

 Adverse Reactions

CV: Arrhythmia (especially bradycardia); hypotension; tachycardia; atrioventricular block; nodal rhythm; non-specific ECG changes; cardiac arrest; syncope. CNS: Convulsions; dysarthria; dysphonia; dizziness; loss of consciousness; drowsiness; headache. DERM: Rash; urticaria; flushing. EENT: Lacrimation; miosis; spasm of accommodation; diplopia; conjunctival hyperemia; visual changes. GI: Increased salivary, gastric and intestinal secretions; nausea; vomiting; dysphagia; increased peristalsis; diarrhea; abdominal cramps; flatulence. GU: Urinary urgency, frequency and incontinence. RESP: Increased tracheobronchial secretions; laryngospasm; bronchiolar constriction; respiratory paralysis; dyspnea; respiratory depression; respiratory arrest; bronchospasm. OTHER: Allergy and anaphylaxis; weakness; fasciculations; muscle cramps and spasms; arthralgia; diaphoresis.

 Precautions

Pregnancy: Pregnancy category undetermined. Lactation: Undetermined. Special risk patients: Use with caution in patients with bronchial asthma, epilepsy, bradycardia, recent coronary occlusion, vagotonia, hyperthyroidism, cardiac arrhythmias or peptic ulcer. Anticholinesterase insensitivity: May develop.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

  • Given IM or IV only.
  • Store at room temperature.

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess neuromuscular status before and frequently during therapy.
  • Obtain baseline ECG and vital signs before therapy and monitor throughout administration.
  • If ECG changes develop (supraventricular tachycardia), notify physician immediately.
  • Take seizure precautions.
  • Keep atropine available in syringe as antidote.
  • Have respiratory support equipment available.
OVERDOSAGE: SIGNS & SYMPTOMS
  Increasing parasympathomimetic action, cholinergic crisis, nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions with resulting bronchial obstruction, bradycardia

 Patient/Family Education

  • Teach patient and family name, desired action, method of administration and potential side effects of edrophonium.
  • Inform patient that effects of medication last up to 30 min after IM administration.
  • Show patient and family how to assess and record changes in muscle strength.
  • Advise patient that urinary urgency and frequency and increased GI motility and secretion will occur and should be reported to physician.

Popularity: 2% [?]


If you're still unable to find appropriate information in the article, please use search form below